RecruitingPhase 1NCT03750513
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Studying Anaplastic ependymoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- David R Grosshans, M.DM.D. Anderson Cancer Center
- Intervention
- Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy(radiation)
- Enrollment
- 48 enrolled
- Eligibility
- 22 years · All sexes
- Timeline
- 2019 – 2027
Study locations (2)
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03750513 on ClinicalTrials.govOther trials for Anaplastic ependymoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05278208Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsNationwide Children's Hospital
- RECRUITINGNANCT05057702Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and EpendymomaUniversity of California, San Francisco